According to a new study, patients with aggressive rheumatoid arthritis (RA) have lower levels of non-esterified fatty acids, which coincide with an enhanced Th1 response. Researchers suggest that lower EPA and DHA at the onset of RA may exacerbate inflammation, and fatty acids may become a novel therapeutic target for the disease…
Gout Treatment & Care Remain Suboptimal
A recent analysis compared the care of patients with RA with that received by patients with gout, finding that hospitalization and costs for patients with gout have increased, but both are decreasing for patients with RA. Unlike RA, significant advances in treatment have not been made for gout, despite its increasing prevalence, and patients may land in the hospital unnecessarily…
The Real Story on RA: Survey Finds Communication Gaps Between Physicians & Patients with RA
Survey results released earlier this year found that communication difficulties exist between patients and their rheumatologists for many reasons—possibly resulting in more disease activity despite advances in RA treatments. Here are tips for communicating with your patients and helping them be more proactive in their care…
Patients with Active RA Have Higher Drug Efflux Transporter Activity
New research examined the peripheral blood in patients with rheumatoid arthritis to investigate the association between disease activity, treatment and the functional activity of ABCB1 and ABCG2 drug efflux transporters. Results showed that transporter activity may correlate with increased disease activity and persist unrelated to treatment for as long as six months in some patients…
Mesoblast Cell Treatment Shows Promise in Rheumatoid Arthritis
(Reuters)—Mesoblast Ltd. on Monday said its experimental stem-cell treatment led to significant improvements of symptoms and disease activity in patients whose rheumatoid arthritis had stopped being helped by widely used biotech medicines, according to data from a mid-stage trial. Treatment with the Australian company’s mesenchymal precursor cell (MPC) product, MPC-300-IV, was deemed well tolerated with…
Generic TNF-Alpha Inhibitors Comparable to Established Brands
NEW YORK (Reuters Health)—Biosimilar tumor necrosis factor-alpha inhibitors appear equivalent to the branded original versions, according to a systematic review and meta-analysis. As Dr. G. Caleb Alexander tells Reuters Health by email, “biologic treatments represent a rapidly growing proportion of prescription drug expenditures and thus there is enormous interest in whether or not biosimilar products…
New RA Therapy Promising in Clinical Trial
Results from a clinical trial support the efficacy of vobarilizumab for treating RA. Plus, the UK will recommend the use of certolizumab pegol to treat severe cases of RA in upcoming guidelines…
Methotrexate with Step-Down Glucocorticoid Remission Induction Works in Early RA
NEW YORK (Reuters Health)—Methotrexate with step-down glucocorticoid remission induction (COBRA Slim) is an effective, safe and feasible initial treatment strategy for patients with early rheumatoid arthritis (RA), researchers from Belgium report. Patients with early RA should be treated rapidly, intensively and to target, according to current guidelines, they note in a paper online July 18…
FDA Panel Backs Amgen Biosimilar of Humira
(Reuters)—Amgen Inc.’s cheaper version of AbbVie’s top-selling arthritis drug adalimumab (Humira) is highly similar to the original and should be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Tuesday. The panel voted 26–0 that the drug, ABP 501, which was studied in rheumatoid arthritis and plaque psoriasis, was similar in…
FDA Staff Says Amgen Biosimilar ‘Highly Similar’ to AbbVie’s Humira
(Reuters)—Amgen Inc’s biosimilar form of AbbVie Inc.’s adalimumab (Humira) arthritis drug, the world’s top-selling medicine, is similarly potent and safe as the original product, according to a preliminary review by staff members of the U.S. Food and Drug Administration (FDA). The assessment precedes an all-day meeting on Tuesday of an independent panel of medical advisers…
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 30
- Next Page »